【商业翻译—医师报约稿】Troxacitabine, Gemcitabine May Be Synergistic ...
这个帖子发布于 17 年零 327 天前，其中的信息可能已发生改变或有所发展。
1.保证质量。
2.本周五中午12点前译者完成编译，周六中午12点之前校对者完成校对，周六晚上8点前译者根据校对的意见修正编译的文章。
3.翻译并非简单直译，格式见版内置顶的文摘编译格式：
http://www.dxy.cn/bbs/post/view?bid=116&id=8600034&sty=1&tpg=1&age=0
4.稿酬按医师报标准(根据质量分为ABC三等，评级由医师报编辑进行)。
5.为保证翻译质量起见，在本版得分超过15分以上的战友方可认领。
6.每位战友最多认领2篇。
7.作者统一署名为"丁香"。
8.文中出现的杂志名称用原文，无需翻译。
9.每认领一篇医师报商业翻译的战友须同时认领一篇当期稿件的校对工作，要在翻译帖和校对帖中分别回复认领翻译及校对。
10.编译要精炼，未特殊注明的，编译后字数最好能控制在300-800字。
Troxacitabine, Gemcitabine May Be Synergistic in Treating Pancreatic Cancer
By Martha Kerr
NEW YORK (Reuters Health) Jul 26 - Preliminary experimental studies in cell lines and in a mouse model of human pancreatic cancer show that gemcitabine and troxacitabine are "more than additive" and appear safe, investigators report in BMC Cancer published online July 3rd.
Dr. Vijaya L. Damaraju of the University of Alberta, Edmonton, Canada, and colleagues exposed four different human pancreatic adenocarcinoma cell lines to troxacitabine (Troxatyl; Thallion Pharmaceuticals) and gemcitabine (Gemzar; Eli Lilly), alone or in combination for 72 hours. Using electronic particle counting, the researchers measured the effects of the various drug treatments on cell growth.
Synergy was observed in all four cell-lines at multiple drug concentrations, resulting in a 50% reduction of cell growth, the investigators report.
In vivo studies of monotherapy or combination therapy were conducted in nude mice with established human pancreatic tumors. The results "indicated that both drugs were more than additive at well-tolerated doses and schedule," the researchers report.
"The biological basis for this synergy is unclear as we did not observe changes in apoptosis, DNA repair, troxacitabine incorporation into DNA or troxacitabine metabolism in the presence of gemcitabine," Dr. Damaraju and colleagues comment.
Co-investigator Dr. Henrietta Gourdeau of Thallion Pharmaceuticals pointed out in comments to Reuters Health, "The standard of care for the treatment of advanced pancreatic cancer is gemcitabine since 1996. It provides clinical benefit response of 22% and survival of 5.65 months (18% for 1 year survival)."
Dr. Gourdeau also noted that "troxacitabine was evaluated in a phase II trial in advanced pancreatic cancer and showed that median survival was 5.6 months (19% for 1 year survival). This is comparable to gemcitabine single agent. Since both agents can be administered at their effective doses, the fact that they are synergistic in animal models warrants that this combination be evaluated in a phase III clinical trial.
BMC Cancer 2007;7.
2.本周五中午12点前译者完成编译，周六中午12点之前校对者完成校对，周六晚上8点前译者根据校对的意见修正编译的文章。
3.翻译并非简单直译，格式见版内置顶的文摘编译格式：
http://www.dxy.cn/bbs/post/view?bid=116&id=8600034&sty=1&tpg=1&age=0
4.稿酬按医师报标准(根据质量分为ABC三等，评级由医师报编辑进行)。
5.为保证翻译质量起见，在本版得分超过15分以上的战友方可认领。
6.每位战友最多认领2篇。
7.作者统一署名为"丁香"。
8.文中出现的杂志名称用原文，无需翻译。
9.每认领一篇医师报商业翻译的战友须同时认领一篇当期稿件的校对工作，要在翻译帖和校对帖中分别回复认领翻译及校对。
10.编译要精炼，未特殊注明的，编译后字数最好能控制在300-800字。
Troxacitabine, Gemcitabine May Be Synergistic in Treating Pancreatic Cancer
By Martha Kerr
NEW YORK (Reuters Health) Jul 26 - Preliminary experimental studies in cell lines and in a mouse model of human pancreatic cancer show that gemcitabine and troxacitabine are "more than additive" and appear safe, investigators report in BMC Cancer published online July 3rd.
Dr. Vijaya L. Damaraju of the University of Alberta, Edmonton, Canada, and colleagues exposed four different human pancreatic adenocarcinoma cell lines to troxacitabine (Troxatyl; Thallion Pharmaceuticals) and gemcitabine (Gemzar; Eli Lilly), alone or in combination for 72 hours. Using electronic particle counting, the researchers measured the effects of the various drug treatments on cell growth.
Synergy was observed in all four cell-lines at multiple drug concentrations, resulting in a 50% reduction of cell growth, the investigators report.
In vivo studies of monotherapy or combination therapy were conducted in nude mice with established human pancreatic tumors. The results "indicated that both drugs were more than additive at well-tolerated doses and schedule," the researchers report.
"The biological basis for this synergy is unclear as we did not observe changes in apoptosis, DNA repair, troxacitabine incorporation into DNA or troxacitabine metabolism in the presence of gemcitabine," Dr. Damaraju and colleagues comment.
Co-investigator Dr. Henrietta Gourdeau of Thallion Pharmaceuticals pointed out in comments to Reuters Health, "The standard of care for the treatment of advanced pancreatic cancer is gemcitabine since 1996. It provides clinical benefit response of 22% and survival of 5.65 months (18% for 1 year survival)."
Dr. Gourdeau also noted that "troxacitabine was evaluated in a phase II trial in advanced pancreatic cancer and showed that median survival was 5.6 months (19% for 1 year survival). This is comparable to gemcitabine single agent. Since both agents can be administered at their effective doses, the fact that they are synergistic in animal models warrants that this combination be evaluated in a phase III clinical trial.
BMC Cancer 2007;7.
